Background. In intensive care (ICU) patients, systemic exposure of β-lactam antibiotics can be altered, and positive clinical outcome is associated with increasing fT > MIC ratios. In sub-Saharan African hospitals, benzylpenicillin (PEN) is frequently used for the empiric treatment of severe pneumococcal infections. Pharmacokinetic data for non-ICU hospitalized populations are lacking.
Pathophysiological changes associated with severe infection and sepsis, such as hypoalbuminemia, edema, and organ dysfunction are known to lead to alterations of volume of distribution and clearance. An increasing amount of evidence shows that such disease-induced pharmacokinetic (PK) changes may give rise to suboptimal antibiotic plasma concentrations and an inability to attain pharmacodynamic (PD) targets, especially among critically ill intensive care (ICU) patients [1, 2] . β-lactam antibiotics are particularly vulnerable in this respect, as they are hydrophilic drugs with predominant renal clearance. For this group of antibiotics, reaching PD targets where the unbound drug concentration remains above minimum inhibitory concentration (MIC) during half of the dosing interval (fT > MIC = 50%) or throughout the dosing interval (fT > MIC = 100%) has been shown to be associated with positive clinical outcome in critically ill patients [3, 4] .
In sub-Saharan Africa (SSA), invasive pneumococcal disease is common and human immunodeficiency virus (HIV) infection predisposes for disease and worsens disease outcome [5] [6] [7] [8] [9] . The β-lactam benzylpenicillin (PEN) has remained one of the most frequently used antibiotics for in-hospital treatment of community-acquired pneumonia and presumptive invasive pneumococcal disease, including sepsis, as it is considered cheap and safe.
In such SSA hospitalized patients, the PK of antibiotics may also be influenced by chronic conditions such as cachexia and liver and kidney dysfunction, resulting from highly prevalent chronic diseases such as tuberculosis, hepatitis B, and hypertension [10] [11] [12] . However, PK/PD data concerning PEN for use in severely ill non-ICU patient populations are lacking, even though underexposure to the active, unbound drug may not only lead to treatment failure [3, 4] , but may also contribute to the emergence of antimicrobial resistance, which is already highly prevalent in South Africa as well as in other SSA countries [13, 14] .
In the present study, we performed a population pharmacokinetic (PPK) analysis of PEN in an adult Mozambican, hospital medicine ward population. The specific aims of the study were to describe the population PK of total PEN (PEN t ) in order to identify factors associated with altered PK. Additionally, we aimed to assess the probability of attaining specified unbound PEN (PEN u ) exposure targets (probability of target attainment [PTA]) with commonly used dosing regimens for the treatment of Streptococcus pneumoniae.
METHODS

Setting
The Beira Central Hospital (HCB) in Mozambique is a 733-bed governmental referral health facility with 260 internal medicine beds. The proportion of patients infected with HIV on its medicine ward may be as high as 74% and up to 30% of hospitalized patients may die during hospital stay [15] .
Study Design
The current study was a prospective, observational PPK study of PEN, as part of a larger PPK study of commonly used antibiotics in adult patients. In this study, PK data were collected from October 2014 until November 2015 from patients who were treated with intravenously administered ceftriaxone, ampicillin, gentamicin, or PEN. The larger PPK study was reviewed and approved by the Mozambican National Committee for Bioethics in Health (CNBS; study registration number 118/CNBS/2013). Additionally, a letter of approval was obtained from the director of the HCB. Participants gave written informed consent. Those unable to read, write, and/or understand Portuguese gave a thumbprint and an impartial, literate witness observed the entire informed consent process and subsequently co-signed the informed consent form.
Recruitment and Data Collection
Patients were eligible for study entry if they were hospitalized on the HCB medicine ward while being treated with 1 or more of the study antibiotics, as documented in a patient's medication record. Inclusion criteria were age ≥18 years and being willing and able to give informed consent. Exclusion criteria were the use of drugs known to significantly affect PK of the study antibiotics (probenecid, phenylbutazone, acetylsalicylic acid, indomethacin), a hemoglobin level ≤6 g/dL as measured by the HCB's laboratory, any condition necessitating a blood transfusion irrespective of hemoglobin level, and an altered level of consciousness. PPK study participants with an intravenous PEN prescription (PEN, Reyoung Pharmaceutical Co. Ltd, Shandong, China) were selected for the present study.
Two trained research nurses captured baseline characteristics and PEN dosing information and measured body weight and length of all study participants. Units of 10 million IU PEN powder for infection were dissolved in 10 mL of sterile water for injection, and the appropriate dose was measured and subsequently injected intravenously via a venous catheter in half a minute, according to the attending physician's prescription. During a minimum of 2 days, a maximum of 4 blood samples were collected for the measurement of PEN concentrations. Sample times were predose (trough level), 30-120 minutes after intravenous administration (peak level) and at 2 random time points during the dosing interval (random levels). PEN administration procedures were observed where possible, and a maximum of 19 mL of blood was collected over a period of ≥2 days. One blood sample was also used for the measurement of albumin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, and creatinine concentrations. Bilirubin levels were not measured, for local practical reasons in relation to bilirubin's high photosensitivity. Creatinine clearance (CrCl) was estimated using the Cockroft and Gault formula [16] .
Sample Handling and Drug Assay
Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood samples were refrigerated at 4°C-8°C immediately after collection until laboratory processing, which took place within 2 hours of collection. Samples were centrifuged and plasma was stored at -80°C in the local research laboratory until shipment on dry ice to the Netherlands for biochemical marker and drug concentration analysis.
To confirm the assumption that PEN t concentrations were representative of PEN u concentrations as a result of linear albumin binding, both PEN t and PEN u were measured in a random 15% selection of all samples with a PEN t concentration above the lower limit of quantification (LLQ). Plasma was ultrafiltrated (centrifugal filters: Millipore Amicon Ultra 0.5 mL/30K, Merck Millipore, Darmstadt, Germany), and the ultrafiltrated plasma was subsequently processed to obtain the PEN u concentration. Thus obtained PEN u concentrations were used to calculate the sample's PEN u fraction. PEN t and PEN u concentrations were measured using a validated high-performance liquid chromatography mass spectrometry (LC-MS) (LC: LC30 UPLC, Shimadzu, Kyoto, Japan/MS: Qtrap 5500 system, Sciex, Framingham, Massachusetts). The LLQ was 0.5 mg/L and the higher limit of quantification was 40 mg/L. Concentrations >40 mg/L were diluted and reanalyzed. Withinand between-assay variability was smaller than 4.8% and 7.0%, respectively. The accuracy of the assay was between 97% and 102%.
Population Pharmacokinetic Analysis
Model Development
PPK analysis was performed using the nonlinear mixed-effects modeling software package NONMEM (7.1.2; Icon Development Solutions, Ellicott City, Maryland). For detailed methodological model building information, see the Supplementary Appendix.
In brief, a PPK model was developed in which the PK of PEN t was described, including its between-patient variability (BPV). Next, patient demographics and pathophysiological factors (covariates) were tested for their correlation with the identified PK parameters from the model in an attempt to explain BPV. Last, the model resulting from the multivariate analysis was tested for its robustness in a bootstrap analysis. The model was validated by performing a visual predictive check (VPC) that investigated whether the final model could adequately predict the observed concentration-time course of PEN t , including the observed variability. Bootstrap and VPC analyses were performed using Perl-speaks-NONMEM version 3.5.3 software (PsN, Uppsala, Sweden).
Monte Carlo Simulations
Using the validated PPK model, PEN t concentration-time profiles were simulated based on Monte Carlo simulations. To visualize the effect of covariates identified, concentration-time profiles of patients with all median characteristics of the population, but with either the median, 10th percentile, or 90th percentile value of a specific covariate, were simulated using the most frequently observed PEN dosing regimen.
To generate insight in the PTA, 4 different dosing regimens were simulated: 1 million international units (IU) or 600 mg every 6 hours (q6h), 3 million IU (1.8 g) q6h, 4 million IU (2.4 g) q6h, and 3 million IU (1.8 g) every 4 hours (q4h). For the simulations of the PTA, 1000 virtual patients were simulated for each dosing regimen. Based on these data and on the median PEN u fraction of 0.45, the PTA, being the percentage of patients with a PEN u concentration remaining above a specified MIC during a specified percentage of time of the dosing interval (fT > MIC), was calculated for different fT > MIC targets. The study endpoints for PTA were fT > MIC = 50% as primary target and fT > MIC = 100%, fT > 4 × MIC = 100%, and fT > 4 × MIC = 50% as secondary targets. The choice of PD targets was based on conclusions of a recent critical appraisal of data concerning β-lactam administration and β-lactam PD targets in critically ill patients [4, 17, 18] . The choice of the range of target MICs was based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical MIC breakpoints for susceptibility and resistance to PEN of S. pneumoniae, where a pathogen with an MIC ≤0.06 mg/L is considered susceptible and one with an MIC >2 mg/L is considered resistant [19] , and on the range of MICs observed in a pilot study on the susceptibility of S. pneumoniae among adult Mozambican hospitalized patients with pneumococcal pneumonia [20] .
RESULTS
Patients and Benzylpenicillin Concentrations
We screened a total of 762 patients for the larger PPK study and excluded 366 patients (Figure 1 ). The most common reasons for exclusion were a hemoglobin level ≤6 g/dL, having received or being scheduled to receive a blood transfusion, or having an altered level of consciousness. We included 115 patients in the current study on PEN and remained with 112 participants for analysis, after removing 3 patients from analysis with PEN t concentrations below the LLQ only, as we supposed that PEN had not been administered. A total of 387 plasma samples yielded 387 PEN t concentrations. Twenty-seven of 387 (6.9%) participants had <4 plasma samples available, with the most common explanations being unforeseen discharge or death. Patient characteristics are presented in Table 1 . A large majority of patients (87.6%) had a 3 million IU (1.8 g) q6h PEN dosing schedule.
There were 45 of 387 (11.6%) samples with a PEN t concentration below the LLQ that had been collected within 4 hours after the last PEN dose. These samples were excluded from further analysis, as they were unlikely PEN t concentrations from a PK perspective, and most likely to have resulted from a missed dose. Consequently, the study remained with 342 samples for final analysis. Eighty-four of 342 (24.5%) PEN t samples with a concentration below the LLQ that had been collected more than 4 hours after the last PEN dose were included in the analysis. The median albumin-bound fraction, based on 53 of 342 (15%) samples, was 55% (interquartile range, 43%-62%). The observed PEN t concentrations are shown in Figure 2 .
Population Pharmacokinetic Analysis
Model Development
For detailed modeling information, including the PK parameter values belonging to the different modeling steps, see the Supplementary Appendix. In brief, model building was performed using observed PEN t concentrations only, as there was a strong correlation between PEN t and PEN u concentrations in the selection of samples for which both PEN t and PEN u concentrations were measured (correlation coefficient, r = 0.98; Figure 3 ). An additional reason not to use PEN u concentrations for model-building purposes was that a large number of PEN u concentrations were projected to be below the LLQ (at least 105; 31%) based on the total number of PEN t concentrations <1 mg/L and a median albumin binding of 55% (Supplementary Appendix). The PEN t data best fitted a 1-compartmental model. The BPV in clearance, expressed as coefficient of variation, was estimated to be 76%. The covariate analysis was based on 100% availability of covariate results, except for 2 patients for whom the hemoglobin level was not captured. These were imputed with median hemoglobin level of the population. Covariate analysis yielded a model with significant associations between PEN t clearance and CrCl, explaining 33% of the BPV. The final model had an adequate fit and the VPC is shown in Figure 2 . The residual variability for the PEN t concentration, an estimate of unexplained variability relating to measurement error, errors in data collection, intrapatient variability, and model misspecification, was 57%.
Monte Carlo Dosing Simulations
The association between PEN clearance and CrCl is illustrated in the concentration-time profiles for the most frequently applied dosing regimen of 3 million IU (1.8 g) q6h and it shows that patients with a higher CrCl had lower PEN t concentrations (Figure 4 ).
For microorganisms with an MIC of 1 mg/L, the PTA of 3 million IU (1.8 g) q6h for patients with the median CrCl of 80 mL/minute was 74.1% for the primary PD target of fT > MIC = 50% (Table 2; Figure 5 ). The PTA of the secondary PD target of fT > MIC = 100%, a target used for severely ill patients, was 24.8%. The different PTAs of the same PD targets for the PEN regimen frequently advised for the treatment of pneumonia, namely 1 million IU (600 mg) q6h, never exceeded 50%. Augmenting the PEN dose or decreasing the PEN dosing interval improved the PTA of the fT > MIC = 100% PD target, although it remained low. When treating a pathogen with an MIC of 0.06 mg/L, which is the EUCAST susceptibility breakpoint, the fT > MIC = 50% PTA was 98.2% for the most frequently used 3 million IU (1.8 g) q6h regimen and 94.7% for the 1 million IU (600 mg) q6h regimen, in patients with the median CrCl of 80 mL/minute ( Figure 5 ). The PTAs of the secondary PD target of fT > MIC = 100% for the same dosing regimens were 72.3% and 56.1%, respectively.
DISCUSSION
This PPK study of PEN provides evidence showing that SSA adult non-ICU patients are at substantial risk for underexposure to PEN u during intermittent bolus dosing with standard dosing regimens. The study population's severity of illness was illustrated by its low median body mass index and low median hemoglobin and plasma albumin concentrations. Similar to critically ill ICU populations, the risk for underexposure is especially high when a patient's renal function is intact and when pathogens with intermediate susceptibility are involved [21, 22] . The BPV of PEN PK was high and a substantial part could be explained by the relationship between PEN clearance and renal function, as can be expected with a predominantly renally cleared drug. Renal function was also the most important factor influencing PK in 2 European studies with PEN [23, 24] , and in 2 studies concerning the use of the mildly albumin-bound and hydrophilic β-lactam piperacillin in critically ill ICU patients [21, 22] . This study's simulations showed that shortening the PEN dosing interval did improve the PTA, even though the probability of the PEN u concentration remaining above the MIC throughout the dosing interval remained low for an infection with a pathogen with an MIC of 1 mg/L. We believe that the use of this MIC is justified, as in an earlier pilot study with adult hospitalized SSA patients with pneumococcal pneumonia, we found 3 of 16 pneumococcal strains recovered from sputum to have an MIC of 0.75 mg/L [20] , while 2 other studies from the region suggested that infections with pneumococcal strains with intermediate susceptibility are not uncommon [25, 26] .
The finding of a high risk of underexposure to PEN during routine intermittent bolus dosing in a severely ill study population is of clinical importance, as recent evidence suggests that in critically ill patients, positive clinical outcome is independently associated with reaching the fT > MIC = 50% and fT > MIC = 100% targets [4, 27, 28] . In addition, critically ill ICU patients treated with continuous β-lactam infusion show improved clinical outcomes compared with patients treated with intermittent bolus dosing while being more likely to achieve the Data are expressed as median (range) unless otherwise indicated. One million IU = 600 mg benzylpenicillin.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; IQR, interquartile range; IU, international units; PEN, benzylpenicillin; PEN t , plasma total benzylpenicillin concentration. a Creatinine clearance estimated using the Cockroft-Gault equation [16] . fT > MIC = 100% PD target. Three recent meta-analyses looking at different selections of studies also came to the conclusion that continuous β-lactam infusion is associated with lower hospital mortality [29] [30] [31] . Combined with evidence suggesting that underexposure promotes the emergence of antimicrobial resistance [32] [33] [34] [35] , it may be legitimate to apply the more stringent β-lactam PD target of fT > MIC = 100% for the current study's severely ill, immunocompromised patient population, even though studies providing such evidence for patients with invasive pneumococcal disease are currently lacking. Our study has limitations. First, we limited our study design to investigating PK/PD and are therefore not able to provide direct evidence for an association between underexposure and clinical outcome. Second, we did not capture information about a patient's fluid balance and the presence of excess fluid in the interstitial and transcellular space. It is our experience that fluid therapy is a relatively neglected part of treatment in adult hospitalized patients in SSA hospitals, and our observations are supported by reports from Uganda [36, 37] . The possibility of an inadequate hydration status may imply that PEN u concentrations as well as PTAs could turn out to be lower than what was found in the current study once proper volume therapy is applied. Third, part of the remaining BPV in clearance may contain a relationship between liver function and PEN elimination that was left unaccounted for, as we did not include bilirubin concentration in our covariate analysis. Fourth, there was substantial residual PK variability as expressed by the PEN t proportional error. Although we cannot exclude that some of the retained concentrations below the LLQ could result from erroneous drug administration, overall, these concentrations fitted the rest of a patient's concentration-time profile, in the sense that these concentrations were likely to be preceded by a sample with a concentration above the LLQ. In addition, the low plasma concentrations from the second half of the dosing interval seem to be in accordance with PEN u concentrations from a PK study with severely ill endocarditis patients treated with a 5 million IU (3 g) q6h PEN dosing regimen [21] . Fifth, our model was built on measured PEN t plasma concentrations only. Even though PEN t and PEN u concentrations correlated well in a random sample of the study population and evidence from other studies also suggests that unbound concentrations of moderately albumin-bound β-lactams such as PEN can be predicted from the total concentrations [38] , we cannot exclude that some bias may have been introduced through this modeling step. Finally, we used the Cockroft and Gault formula for the estimation of CrCl, which in underweight, severely ill patients may have resulted in an overestimation of the renal function.
Even though studies investigating antibiotic PK in non-SSA ICU patient populations show comparable tendencies toward underexposure [23, 24] , extrapolations to non-SSA severely ill (ICU) patient populations should be made with caution, as our study population is likely to differ from other populations in terms of underlying sufferings and treatment aspects, such as antibiotic infusion time and fluid therapy. In conclusion, this study's results indicate that intermittent bolus dosing of the β-lactam antibiotic PEN in non-ICU severely ill adult SSA patients, similar to ICU patients, is likely to lead to underexposure to PEN u , especially when their renal function is intact. Although underexposure was projected to occur more frequently when treating pathogens with higher MICs, even infections with pathogens that would normally be considered susceptible could suffer from severe undertreatment. There is a need for clinical PK/PD studies in SSA settings against the background of locally derived MICs.
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